TY - JOUR
KW - General Medicine
KW - Geospatial analysis
KW - Global distribution
AU - Cromwell EA
AU - Schmidt CA
AU - Kwong KT
AU - Pigott DM
AU - Mupfasoni D
AU - Biswas G
AU - Shirude S
AU - Hill E
AU - Donkers KM
AU - Abdoli A
AU - Abrigo MRM
AU - Adekanmbi V
AU - Adetokunboh OO
AU - Adinarayanan S
AU - Ahmadpour E
AU - Ahmed MB
AU - Akalu TY
AU - Alanezi FM
AU - Alanzi TM
AU - Alinia C
AU - Alipour V
AU - Amit A
AU - Anber NH
AU - Ancuceanu R
AU - Andualem Z
AU - Anjomshoa M
AU - Ansari F
AU - Antonio CAT
AU - Anvari D
AU - Appiah SCY
AU - Arabloo J
AU - Arnold B
AU - Ausloos M
AU - Ayanore MA
AU - Badirzadeh A
AU - Baig AA
AU - Banach M
AU - Baraki AG
AU - Bärnighausen TW
AU - Bayati M
AU - Bhattacharyya K
AU - Bhutta ZA
AU - Bijani A
AU - Bisanzio D
AU - Bockarie MJ
AU - Bohlouli S
AU - Bohluli M
AU - Butt ZA
AU - Cano J
AU - Carvalho F
AU - Chattu VK
AU - Chavshin AR
AU - Cormier NM
AU - Damiani G
AU - Dandona L
AU - Dandona R
AU - Darwesh AM
AU - Daryani A
AU - Dash AP
AU - Deribe K
AU - Deshpande A
AU - Dessu BK
AU - Dhimal M
AU - Dianatinasab M
AU - Diaz D
AU - Do HT
AU - Earl L
AU - El Tantawi M
AU - Faraj A
AU - Fattahi N
AU - Fernandes E
AU - Fischer F
AU - Foigt NA
AU - Foroutan M
AU - Guo Y
AU - Hailu GB
AU - Hasaballah AI
AU - Hassankhani H
AU - Herteliu C
AU - Hidru HDD
AU - Hole MK
AU - Hon J
AU - Hossain N
AU - Hosseinzadeh M
AU - Househ M
AU - Humayun A
AU - Ilesanmi OS
AU - Ilic IM
AU - Ilic MD
AU - Iqbal U
AU - Irvani SSN
AU - Islam MM
AU - Jha R
AU - Ji JS
AU - Johnson KB
AU - Jozwiak JJ
AU - Kabir A
AU - Kalankesh LR
AU - Kalhor R
AU - Karami Matin B
AU - Karch A
AU - Karimi SE
AU - Kasaeian A
AU - Kayode GA
AU - Kazemi Karyani A
AU - Kelbore AG
AU - Khafaie MA
AU - Khalilov R
AU - Khan J
AU - Khatab K
AU - Khater MM
AU - Khodayari MT
AU - Kianipour N
AU - Kim YJ
AU - Kinyoki DK
AU - Kumar GA
AU - Kusuma D
AU - La Vecchia C
AU - Lansingh VC
AU - Lee PH
AU - LeGrand KE
AU - Levine AJ
AU - Li S
AU - Maleki S
AU - Mansournia MA
AU - Martins-Melo FR
AU - Massenburg BB
AU - Mayala BK
AU - Meitei WB
AU - Mendoza W
AU - Mengistu DT
AU - Mereta ST
AU - Mestrovic T
AU - Mihretie KM
AU - Miller-Petrie MK
AU - Mohammadian-Hafshejani A
AU - Mohammed S
AU - Mokdad AH
AU - Moradi M
AU - Moradzadeh R
AU - Moraga P
AU - Morrison SD
AU - Mosser JF
AU - Mousavi SM
AU - Munro SB
AU - Muthupandian S
AU - mwingira UJ
AU - Naderi M
AU - Nagarajan AJ
AU - Naik G
AU - Negoi I
AU - Nguyen TH
AU - Nguyen HLT
AU - Olagunju AT
AU - Omar Bali A
AU - Osarenotor O
AU - Osei FB
AU - Pasupula DK
AU - Pirsaheb M
AU - Pourjafar H
AU - Rathi P
AU - Rawaf DL
AU - Rawaf S
AU - Rawassizadeh R
AU - Reiner RC
AU - Reta MA
AU - Rezapour A
AU - Ribeiro AI
AU - Rostami A
AU - Sabesan S
AU - Sadeghi E
AU - Sajadi SM
AU - Samy AM
AU - Sartorius B
AU - Schaeffer LE
AU - Shaikh MA
AU - Sharafi K
AU - Sharafi Z
AU - Sharifi H
AU - Shibuya K
AU - Shin JI
AU - Soheili A
AU - Soltani S
AU - Spotin A
AU - Stolk W
AU - Tesfay BE
AU - Topor-Madry R
AU - Tran KB
AU - Tran BX
AU - Ullah I
AU - Unnikrishnan B
AU - Vasseghian Y
AU - Vinkeles Melchers NVS
AU - Violante FS
AU - Yamada T
AU - Yaya S
AU - Yazdi-Feyzabadi V
AU - Yip P
AU - Yonemoto N
AU - Zaki L
AU - Zaman SB
AU - Zamanian M
AU - Zangeneh A
AU - Zhang Z
AU - Zhang Y
AU - Ziapour A
AU - King J
AU - Hay SI
AB - Background
Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to eliminate lymphatic filariasis as a public health problem. This study aims to produce the first geospatial estimates of the global prevalence of lymphatic filariasis infection over time, to quantify progress towards elimination, and to identify geographical variation in distribution of infection.
Methods
A global dataset of georeferenced surveyed locations was used to model annual 2000–18 lymphatic filariasis prevalence for 73 current or previously endemic countries. We applied Bayesian model-based geostatistics and time series methods to generate spatially continuous estimates of global all-age 2000–18 prevalence of lymphatic filariasis infection mapped at a resolution of 5 km2 and aggregated to estimate total number of individuals infected.
Findings
We used 14 927 datapoints to fit the geospatial models. An estimated 199 million total individuals (95% uncertainty interval 174–234 million) worldwide were infected with lymphatic filariasis in 2000, with totals for WHO regions ranging from 3·1 million (1·6–5·7 million) in the region of the Americas to 107 million (91–134 million) in the South-East Asia region. By 2018, an estimated 51 million individuals (43–63 million) were infected. Broad declines in prevalence are observed globally, but focal areas in Africa and southeast Asia remain less likely to have attained infection prevalence thresholds proposed to achieve local elimination.
Interpretation
Although the prevalence of lymphatic filariasis infection has declined since 2000, MDA is still necessary across large populations in Africa and Asia. Our mapped estimates can be used to identify areas where the probability of meeting infection thresholds is low, and when coupled with large uncertainty in the predictions, indicate additional data collection or intervention might be warranted before MDA programmes cease.
BT - The Lancet Global Health
DO - 10.1016/s2214-109x(20)30286-2
IS - 9
LA - eng
N2 - Background
Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to eliminate lymphatic filariasis as a public health problem. This study aims to produce the first geospatial estimates of the global prevalence of lymphatic filariasis infection over time, to quantify progress towards elimination, and to identify geographical variation in distribution of infection.
Methods
A global dataset of georeferenced surveyed locations was used to model annual 2000–18 lymphatic filariasis prevalence for 73 current or previously endemic countries. We applied Bayesian model-based geostatistics and time series methods to generate spatially continuous estimates of global all-age 2000–18 prevalence of lymphatic filariasis infection mapped at a resolution of 5 km2 and aggregated to estimate total number of individuals infected.
Findings
We used 14 927 datapoints to fit the geospatial models. An estimated 199 million total individuals (95% uncertainty interval 174–234 million) worldwide were infected with lymphatic filariasis in 2000, with totals for WHO regions ranging from 3·1 million (1·6–5·7 million) in the region of the Americas to 107 million (91–134 million) in the South-East Asia region. By 2018, an estimated 51 million individuals (43–63 million) were infected. Broad declines in prevalence are observed globally, but focal areas in Africa and southeast Asia remain less likely to have attained infection prevalence thresholds proposed to achieve local elimination.
Interpretation
Although the prevalence of lymphatic filariasis infection has declined since 2000, MDA is still necessary across large populations in Africa and Asia. Our mapped estimates can be used to identify areas where the probability of meeting infection thresholds is low, and when coupled with large uncertainty in the predictions, indicate additional data collection or intervention might be warranted before MDA programmes cease.
PB - Elsevier BV
PY - 2020
SP - e1186
EP - e1194
T2 - The Lancet Global Health
TI - The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis
UR - https://reader.elsevier.com/reader/sd/pii/S2214109X20302862?token=F07E426B1AF5BAAAFA2922DE4E9AB43112658F6A3812B00D0AD0966F7220D8559ED9C4537B118E1498F89D7EDE3C3BDD
VL - 8
SN - 2214-109X
ER -